HIF1A and cancer: Based on these facts, it seems feasible that SGLT2i can block HIF-1α and thereby change metabolism in cancer cells or stromal fibroblasts, and we might speculate that they could lead to a slower cell division and a lower rate of mitogenesis, which could contribute to the results seen in our study on an early divergence of the cancer-survival curves.